Insider Selling: DexCom, Inc. (NASDAQ:DXCM) CFO Sells $85,712.25 in Stock

DexCom, Inc. (NASDAQ:DXCMGet Free Report) CFO Jereme M. Sylvain sold 745 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $85,712.25. Following the sale, the chief financial officer now owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

DexCom Trading Down 2.9 %

Shares of DXCM stock opened at $113.81 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a market cap of $45.26 billion, a price-to-earnings ratio of 73.43, a PEG ratio of 2.85 and a beta of 1.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a fifty day moving average price of $128.03 and a 200-day moving average price of $125.80.

DexCom (NASDAQ:DXCMGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, equities analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Crewe Advisors LLC bought a new position in shares of DexCom in the first quarter worth approximately $29,000. DSM Capital Partners LLC purchased a new position in shares of DexCom during the 4th quarter valued at $28,000. Riverview Trust Co bought a new position in DexCom in the 1st quarter worth $32,000. Valley National Advisers Inc. increased its stake in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, MV Capital Management Inc. raised its holdings in DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Redburn Atlantic initiated coverage on DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target on the stock. Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. UBS Group boosted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.94.

View Our Latest Stock Analysis on DXCM

DexCom Company Profile

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with's FREE daily email newsletter.